KCPT
NVO

Kingstone Capital Partners Texas’s Novo Nordisk NVO Stock Holding History

Kingstone Capital Partners Texas’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,318
Closed -$230K – 61
2025
Q1 		$230K Hold
3,318
– – 0.19% 44
2024
Q4 		$285K Buy
+3,318
New +$359K 0.23% 40

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kingstone Capital Partners Texas's NVO Position: Q2 2025 in Review

Kingstone Capital Partners Texas sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 3,318 shares — an estimated $230K sold.

Kingstone Capital Partners Texas first reported a position in NVO in Q4 2024 and held it in 2 quarters. The position peaked at $285K in Q4 2024. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Kingstone Capital Partners Texas reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Kingstone Capital Partners Texas sold 3,318 Novo Nordisk shares in Q2 2025, an estimated $230K.
  • Kingstone Capital Partners Texas first reported a position in Novo Nordisk in Q4 2024 and held it in 2 quarters.
  • Kingstone Capital Partners Texas's Novo Nordisk position peaked at $285K in Q4 2024.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Kingstone Capital Partners Texas's 13F filing for Q2 2025, filed 11 Jul 2025.